Evidence map›Paper›PMID 33436675›Full record

ArticleScientific reports2021

Complex of human Melanotransferrin and SC57.32 Fab fragment reveals novel interdomain arrangement with ferric N-lobe and open C-lobe.

Kristyn Hayashi, Kenton L Longenecker, Yi-Liang Liu, Bryan Faust, Aditi Prashar, Johannes Hampl, Vincent Stoll, Sandro Vivona

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03316794 (An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03316794 phase1terminatednot on this map

An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

TypeinterventionalSponsorAbbVieRan2018 to 2018Enrolled2ConditionsBreast CancerArmsSC-005
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Kristyn Hayashi *Research and Development, AbbVie Inc., South San Francisco, CA, 94080, USA.
Kenton L Longenecker *Research and Development, AbbVie Inc., North Chicago, IL, 60064, USA.
Yi-Liang LiuResearch and Development, AbbVie Inc., South San Francisco, CA, 94080, USA.
Bryan FaustResearch and Development, AbbVie Inc., South San Francisco, CA, 94080, USA.
Aditi PrasharResearch and Development, AbbVie Inc., South San Francisco, CA, 94080, USA.
Johannes HamplResearch and Development, AbbVie Inc., South San Francisco, CA, 94080, USA.
Vincent StollResearch and Development, AbbVie Inc., North Chicago, IL, 60064, USA.
Sandro VivonaResearch and Development, AbbVie Inc., South San Francisco, CA, 94080, USA. sandrovivona@gmail.com.
AbbVie (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanotransferrin (MTf) is an iron-binding member of the transferrin superfamily that can be membrane-anchored or secreted in serum. On cells, it can mediate transferrin-independent iron uptake and promote proliferation. In serum, it is a transcytotic iron transporter across the blood-brain barrier. MTf has been exploited as a drug delivery carrier to the brain and as an antibody-drug conjugate (ADC) target due to its oncogenic role in melanoma and its elevated expression in triple-negative breast cancer (TNBC). For treatment of TNBC, an MTf-targeting ADC completed a phase I clinical trial (NCT03316794). The structure of its murine, unconjugated Fab fragment (SC57.32) is revealed here in complex with MTf. The MTf N-lobe is in an active and iron-bound, closed conformation while the C-lobe is in an open conformation incompatible with iron binding. This combination of active and inactive domains displays a novel inter-domain arrangement in which the C2 subdomain angles away from the N-lobe. The C2 subdomain also contains the SC57.32 glyco-epitope, which comprises ten protein residues and two N-acetylglucosamines. Our report reveals novel features of MTf and provides a point of reference for MTf-targeting, structure-guided drug design.

Indexed as

Protein DomainsAcetylglucosamineAnimalsBiological TransportBlood-Brain BarrierDrug Delivery SystemsDrug DesignGene ExpressionHumansImmunoglobulin Fab FragmentsIronMacaca fascicularisMelanomaMembrane GlycoproteinsMiceProtein BindingAcetylglucosamineImmunoglobulin Fab FragmentsIronMELTF protein, humanMembrane Glycoproteins

Identifiers

PMID33436675
PMCPMC7804310
OpenAlexW3118244739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.